

Item: 12.2

REPORT CLASSIFICATION	✓	CATEGORY OF PAPER	✓
Official	✓	Proposes specific action	
Official: Sensitive Commercial		Provides assurance	✓
Official: Sensitive Personal		For information only	

BOARD
26 NOVEMBER 2024

Report Title:	Quality and Safety Committee Highlight Report and Confirmed Minutes
----------------------	----------------------------------------------------------------------------

Purpose of report

To provide the Board with a summary of the key points from the meeting of the Quality and Safety Committee held on 12 September 2024 and the confirmed minutes.

Key points

The Committee considered several issues and supporting papers at its meeting held on 12 September 2024 and the key points are summarised below.

- Quality Report** - The report provided the Committee with oversight of key quality themes, risks and exceptions outlined in the ICB Area Quality reports for Central, North, North Cumbria and South. Updates and assurance were provided on a number of areas including: Never Events - were increasing in the North, this issue had been discussed at quality and oversight meetings. The PSIRF new methodology was being used to investigate these; Healthcare Associated Infection (HCAI) rate increases and plans in place to address; concerns across the ICB in relation to a small number of incidents involving patients with a Learning Disability (LD) within intensive care units who had been intubated and ventilated to manage their behaviour and compliance with treatment – resulting discussion concerning the patient safety alerts issued across the system and plans in place with system partners to gain assurances.
- Safeguarding Annual report** - Due to a timing issue the report had been received by the ICB Board and approved prior to being received at this meeting. The report gave assurance to the committee regarding our ICB safeguarding functions and outlined the continued fulfilment of our statutory safeguarding duties. The report will be shared with relevant safeguarding partnerships and Corporate Parenting Boards for assurance purposes.
- Medicines Optimisation Annual Report** - The report provided an update and assurance for the period April 2023 to March 2024 on quality and safety associated with medicines optimisation in the ICB. It was explained that due to organisational change and operational challenges the medicines optimisation team had reduced by around 30% with a vacancy rate of 40%. Regardless of these constraints the team had continued to work proactively and reactively regarding emerging safety issues and managing medicines shortages.
- LeDeR Annual Report** - The report provided the Committee with the LeDeR Annual Report 1st Jan – 31st Dec 2023. Last year 257 notifications had been received to the LeDeR platform with 216 reviews carried out, 208 were about people with a learning disability and 8 with autism. 41 reviews had not been completed in 2023; an addendum would be added to the report once they had been completed.

- **Neurorehabilitation** – The Committee received a presentation which outlined progress and recommended next steps since the set-up of the Neurorehabilitation Programme Board and a recent stocktake of priorities following the outcome of commissioning intentions for 2024/2025.
- **Clinical Effectiveness update** - An update was provided on the establishment of clinical effectiveness (CE) subcommittee which was approved at Executive Committee in July. The first meeting would be held in October.

Risks and issues

The Committee will continue to receive and review the corporate risks aligned to the quality and safety portfolio to provide assurance to the Board that the quality and safety risks contained within the corporate risk register reflect the current environment.

Assurances and supporting documentation

The Committee received several items for assurance including:

- Integrated Delivery Report – providing an overview of quality and performance, highlighting any significant changes, areas of risk and mitigating actions.
- ICB quality exception report - oversight of key quality themes, risks and exceptions outlined in the ICB Area Quality reports for Central, North, North Cumbria and South.
- Patient Involvement and Experience update
- Area Quality and Safety Subcommittee Minutes
- System Quality Group minutes
- Safeguarding Health Executive minutes

Recommendation/action required

The Board is asked to note the key highlights from the meeting held on 12 September 2024 receive the confirmed minutes from this meeting for information and assurance.

Acronyms and abbreviations explained

As described in the report.

Sponsor/approving executive director	Sir Pali Hungin, Chair of Quality and Safety Committee and Independent Non Executive Member Ann Fox, Interim Chief Nurse
Date approved by executive director	15/11/2024
Report author	Neil Hawkins, Strategic Head of Corporate Governance

Link to ICP strategy priorities (please tick all that apply)

Longer and Healthier Lives	✓
Fairer Outcomes for All	✓
Better Health and Care Services	✓
Giving Children and Young People the Best Start in Life	✓

Relevant legal/statutory issues

Note any relevant Acts, regulations, national guidelines etc

Any potential/actual conflicts of interest associated with the paper? (please tick)	Yes		No	✓	N/A	
Equality analysis completed (please tick)	Yes		No		N/A	✓

If there is an expected impact on patient outcomes and/or experience, has a quality impact assessment been undertaken? (please tick)	Yes		No		N/A	<input checked="" type="checkbox"/>
Key considerations						
Financial implications and considerations	N/A					
Digital implications	N/A					
Clinical involvement	Clinical representation within the committee					
Health inequalities	N/A					
Patient and public involvement	The committee receives regular updates concerning patient and public engagement					
Partner and/or other stakeholder engagement	N/A					
Other resources	N/A					